Besides, as TKI is becoming the treatment of choice in EGFR gene mutated advanced NSCLC patients, the role of COX-2 positivity on patient's response to TKI might be worthy of further investigation with larger samples. Here, PTGS2 is linked to non-small cell lung carcinoma.